LncRNA CCAT2 expression at diagnosis predicts imatinib response in chronic phase chronic myeloid leukemia patients

Shehata, A.; Gohar, Suzy; Muharram, Nashwa M.; Eldin, Samar M Kamal

doi:10.1016/j.leukres.2022.106838

Cited by 7 publications

(6 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 102 The lncRNA CCAT2 was upregulated in the peripheral blood of CML patients and associated with therapy response, as the enhanced expression of CCAT2 at diagnosis indicates imatinib resistance in CML. 73 A higher level of lncRNA TUG1 was found to be negatively correlated with complete remission within 4 weeks, total complete remission, and allogeneic HSCT achievement in adult Ph − ALL. 103 Therefore, correlations between leukemia patient treatment outcome and lncRNA expression/function have been identified by multiple studies.…”

Section: Future Perspectives On Lncrna ‐Based Stra...mentioning

confidence: 89%

“…Interestingly, the post‐treatment HOTAIR expression level was found to be correlated to relapse‐free survival and might predict relapse susceptibility 102 . The lncRNA CCAT2 was upregulated in the peripheral blood of CML patients and associated with therapy response, as the enhanced expression of CCAT2 at diagnosis indicates imatinib resistance in CML 73 . A higher level of lncRNA TUG1 was found to be negatively correlated with complete remission within 4 weeks, total complete remission, and allogeneic HSCT achievement in adult Ph − ALL 103 .…”

Section: Future Perspectives On Lncrna‐based Strategies To Improve Tr...mentioning

confidence: 99%

See 1 more Smart Citation

Long non‐coding RNAs regulate treatment outcome in leukemia: What have we learnt recently?

Shi

Gao

Zhang³

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

show abstract

Section: Future Perspectives On Lncrna ‐Based Stra...mentioning

confidence: 89%

Section: Future Perspectives On Lncrna‐based Strategies To Improve Tr...mentioning

confidence: 99%

Long non‐coding RNAs regulate treatment outcome in leukemia: What have we learnt recently?

Shi

Gao

Zhang³

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Mechanistically, HULC was found to regulate the PI3K/AKT pathway by depleting miR-150-5p and thereby modulating MCL1 expression (Han and Ma, 2021). The lncRNA CCAT2 was found to be highly expressed in CML patients and was linked to IM resistance, suggesting that it is a reliable molecular marker for predicting IM responses in CML patients in the CP (Shehata et al, 2022). Liu J. et al (2022) have shown that the lncRNA HOTTIP, which is highly expressed in IM-resistant patients and cell lines, recruits EZH2 to suppress the expression of the PTEN gene contributing to IM resistance.…”

Section: Implications Of Lncrnas In Im Resistancementioning

confidence: 99%

“…The expression patterns of MEG3 and its targets miR-147 and miR-21 could thus be used as potential biomarkers for early diagnosis of CML blast crisis (Li et al, 2018c(Li et al, , 2018b. A study on peripheral blood mononuclear cells from 43 newly diagnosed CML patients showed that enhanced expression of CCAT2 was associated with IM resistance (Shehata et al, 2022); the authors concluded that CCAT2 can therefore be used as a reliable molecular marker for predicting IM responses in CP CML patients. Expression of HAND2-AS1 in the bone-marrow samples of 30 CML patients showed a gradual decline in its level with disease progression from AP to BP to CP; an inverse correlation between HAND2-AS1 and miR-1275 was also shown in the study (Yang et al, 2019).…”

Section: Lncrnas As Biomarkers In Myeloid Leukemiamentioning

confidence: 99%

Long non-coding RNAs: emerging functional players in the pathobiology and progression of myeloid leukemia

Dutta,

Akhade,

Choudhury

et al. 2024

Front. RNA Res.

View full text Add to dashboard Cite

Advancements and innovations in transcriptomics and computational biology have revealed long non-coding RNAs (lncRNAs) as some of the major regulators of essential biological processes. Their restricted spatial and temporal expressions as well as ability to interact with nucleic acids (DNA and RNA) and proteins make them key players in chromosome integrity, genomic architecture, and transcriptional and post-transcriptional regulation. Their dysregulation has been associated with numerous diseases and pathological conditions, including cancers. Myeloid leukemia is a malignancy of the hematopoietic system, and its pathobiology has been found to have increasing number of lncRNAs with functional significance. This comprehensive review summarizes a majority of the reported lncRNAs in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), focusing on the regulatory mechanisms by which they modulate the disease progression and pathogenesis, their potential as diagnostics and prognostic markers, and their feasibility as novel therapeutic targets. We also highlight our recent work on the significance of the lncRNA Hmrhl in CML, which has been found to regulate gene transcription at the chromatin level.

show abstract

“…While there are contradictory studies on the function of NEAT1 in CML, no studies have yet explored the role of CCAT2 in CML, although one has shown lncRNA CCAT2 is dysregulated in CML, with unusually high expression in the CP of CML compared to healthy controls. Thus, it offers promise as biomarker for CML, but further studies could reveal a therapeutic potential as well [ 131 ].…”

Section: The Role Of Lncrnas In CMLmentioning

confidence: 99%

Non-Coding RNAs Are Implicit in Chronic Myeloid Leukemia Therapy Resistance

Rudich

Garzon

Dorrance

2022

IJMS

View full text Add to dashboard Cite

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm initiated by the presence of the fusion gene BCR::ABL1. The development of tyrosine kinase inhibitors (TKIs) highly specific to p210BCR-ABL1, the constitutively active tyrosine kinase encoded by BCR::ABL1, has greatly improved the prognosis for CML patients. Now, the survival rate of CML nearly parallels that of age matched controls. However, therapy resistance remains a persistent problem in the pursuit of a cure. TKI resistance can be attributed to both BCR::ABL1 dependent and independent mechanisms. Recently, the role of non-coding RNAs (ncRNAs) has been increasingly explored due to their frequent dysregulation in a variety of malignancies. Specifically, microRNAs (miRNAs), circular RNAs (circRNAs), and long non-coding RNAs (lncRNAs) have been shown to contribute to the development and progression of therapy resistance in CML. Since each ncRNA exhibits multiple functions and is capable of controlling gene expression, they exert their effect on CML resistance through a diverse set of mechanisms and pathways. In most cases ncRNAs with tumor suppressing functions are silenced in CML, while those with oncogenic properties are overexpressed. Here, we discuss the relevance of many aberrantly expressed ncRNAs and their effect on therapy resistance in CML.

show abstract

LncRNA CCAT2 expression at diagnosis predicts imatinib response in chronic phase chronic myeloid leukemia patients

Cited by 7 publications

References 34 publications

Long non‐coding RNAs regulate treatment outcome in leukemia: What have we learnt recently?

Long non‐coding RNAs regulate treatment outcome in leukemia: What have we learnt recently?

Long non-coding RNAs: emerging functional players in the pathobiology and progression of myeloid leukemia

Non-Coding RNAs Are Implicit in Chronic Myeloid Leukemia Therapy Resistance

Contact Info

Product

Resources

About